Asset
EPETRABOROLE
AN2 Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05283746 | phase1 | completed | 2022-02-21 | 2022-06-10 | AN2 Therapeutics, Inc | A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function |
| NCT05995444 | phase1 | completed | 2023-06-05 | 2023-07-26 | AN2 Therapeutics, Inc | A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects |
| NCT04892641 | phase1 | completed | 2021-06-10 | 2022-02-26 | AN2 Therapeutics, Inc | Phase 1 Study of Epetraborole Tablets |
| NCT05327803 | phase2_3 | terminated | 2022-05-20 | 2024-12-18 | AN2 Therapeutics, Inc | Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease |
FDA applications (0)
This company has no applications containing this asset.